SCHEDULE 13G/A: Canaan Entities Disclose Significant Beneficial Ownership in Tyra Biosciences
Beneficial Ownership Report
Canaan XI L.P. and its affiliated entities have filed an amended Schedule 13G, reporting a combined beneficial ownership of Tyra Biosciences, Inc. common stock as of December 31, 2024.
Summary
- Canaan XI L.P. and its general partner, Canaan Partners XI LLC, collectively report beneficial ownership of 3,731,165 shares of Tyra Biosciences, Inc. common stock, representing approximately 7.4% of the outstanding shares.
- Canaan 2020+ Co-Investment L.P. Series 7 and its general partner, Canaan Partners 2020+ Co-Investment LLC, collectively report beneficial ownership of 448,692 shares of Tyra Biosciences, Inc. common stock, representing approximately 0.9% of the outstanding shares.
- All reporting persons hold sole voting power and sole dispositive power over their respective beneficially owned shares.
- The reported percentages are based on 50,602,991 shares of Tyra Biosciences, Inc. Common Stock outstanding as of November 4, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment as it does not contain operational or financial performance updates for the issuer.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by institutional investors in a publicly traded biotechnology company, Tyra Biosciences, Inc. It reflects a passive investment stake by the Canaan entities, which are venture capital firms, consistent with their typical investment strategies in early-stage or growth companies.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency regarding significant institutional ownership in Tyra Biosciences, Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-11-04 | Date as of which 50,602,991 shares of Common Stock were outstanding, as disclosed in the Issuer's Form 10-Q. |
| 2024-11-07 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC, disclosing outstanding shares. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date for ownership snapshot). |
| 2025-01-21 | Date the Schedule 13G Amendment No. 1 was signed and filed with the SEC. |
Keywords
Tyra Biosciences, Canaan XI L.P., Canaan Partners XI LLC, Canaan 2020+ Co-Investment L.P. Series 7, Canaan Partners 2020+ Co-Investment LLC, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.